Jeffrey D. Capello's most recent trade in Neogen Corp. was a trade of 2,025 Common Stock done at an average price of $6.2 . Disclosure was reported to the exchange on Oct. 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.19 per share. | 27 Oct 2025 | 2,025 | 30,725 (0%) | 0% | 6.2 | 12,535 | Common Stock |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2025 | 2,025 | 4,050 | - | - | Restricted Stock Units | |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2025 | 1,777 | 1,777 | - | - | Restricted Stock Units | |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.19 per share. | 27 Oct 2025 | 1,777 | 32,502 (0%) | 0% | 6.2 | 11,000 | Common Stock |
| Neogen Corp | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Oct 2025 | 50,814 | 50,814 | - | - | Common Stock (Right to Buy) | |
| Neogen Corp | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 6.07 per share. | 23 Oct 2025 | 19,769 | 48,469 (0%) | 0% | 6.1 | 119,998 | Common Stock |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2025 | 2,071 | 0 | - | - | Restricted Stock Units | |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.63 per share. | 07 Oct 2025 | 2,071 | 28,700 (0%) | 0% | 5.6 | 11,660 | Common Stock |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 2,861 | 2,861 | - | - | Restricted stock units | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 6,073 (0%) | 0% | 0 | Common stock | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 1,977 | 3,953 (0%) | 0% | 0 | Common stock | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 1,977 | 1,976 | - | - | Restricted stock units | |
| Neogen Corp | Jeffrey D. Capello | Director | Purchase of securities on an exchange or from another person at price $ 4.84 per share. | 22 Apr 2025 | 20,712 | 26,629 (0%) | 0% | 4.8 | 100,217 | Common Stock |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.81 per share. | 28 Oct 2024 | 1,776 | 5,917 (0%) | 0% | 13.8 | 24,527 | Common Stock |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 1,776 | 3,552 | - | - | Restricted Stock Units | |
| Neogen Corp | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 18,653 | 18,653 | - | - | Common Stock (Right to Buy) | |
| Neogen Corp | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 13.58 per share. | 24 Oct 2024 | 6,075 | 15,840 | - | 13.6 | 82,499 | Restricted Stock Units |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 2,070 | 2,071 | - | - | Restricted Stock Units | |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.07 per share. | 07 Oct 2024 | 2,070 | 4,141 (0%) | 0% | 15.1 | 31,195 | Common Stock |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 1,976 | 1,976 (0%) | 0% | 0 | Common stock | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 1,976 | 3,953 | - | - | Restricted stock units | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 33,177 | 33,177 | - | - | Stock options (right to buy) | |
| Agios Pharma Inc | Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 5,929 | 5,929 | - | - | Restricted stock units | |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2022 | 18,416 | 18,416 | - | - | Common Stock (Right to Buy) | |
| Neogen Corp | Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2022 | 6,212 | 6,212 | - | - | Restricted Stock Units |